21.08 03:23 | dpa-AFX: FDA Issues Complete Response Letter For Regeneron's Linvoseltamab In R/R Multiple Myeloma |
05.08 06:00 | dpa-AFX: *RPT/DZ BANK RAISES FAIR VALUE FOR REGENERON TO 1218 (1065) USD - 'BUY' |
05.08 06:00 | dpa-AFX: *WDH/DZ BANK HEBT FAIREN WERT FÜR REGENERON AUF 1218 (1065) USD - 'KAUFEN' |
02.08 17:35 | dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR REGENERON AUF 1218 (1065) USD - 'KAUFEN' |
02.08 17:35 | dpa-AFX: *DZ BANK RAISES FAIR VALUE FOR REGENERON TO 1218 (1065) USD - 'BUY' |
01.08 12:59 | dpa-AFX: ROUNDUP: Regeneron Pharma Q2 Results Top Estimates |
01.08 12:50 | dpa-AFX: *REGENERON PHARMA Q2 GAAP NET INCOME $1.432 BLN; NON-GAAP NET INCOME $1.351 BLN |
01.08 12:49 | dpa-AFX: *REGENERON PHARMA Q2 REVENUES UP 12% TO $3.55 BLN |
01.08 12:33 | dpa-AFX: *REGENERON PHARMA Q2 GAAP EPS $12.41; NON-GAAP EPS $11.56 |
30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
10.07 09:53 | dpa-AFX: *BARCLAYS HEBT ZIEL FÜR REGENERON PHARMA AUF 1200 (1050) USD - 'OVERWEIGHT' |
10.07 09:53 | dpa-AFX: *BARCLAYS RAISES REGENERON PHARMA PRICE TARGET TO 1200 (1050) USD - 'OVERWEIGHT' |
08.07 14:05 | dpa-AFX: Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge |
08.07 13:58 | dpa-AFX: *REGENERON ANTICIPATES $24 MLN R&D CHARGE IN Q2 RESULTS |
03.07 08:15 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
03.07 08:15 | Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
03.07 08:10 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
03.07 07:39 | Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie |
03.07 07:31 | dpa-AFX: Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients |
|